Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.36 |
| ▸ | GSR | P00390 | 1/20 | 0.34 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1053261 | 0.89 | CPB2 (0.34) | CPB2GSRRNPEPHDAC1HDAC2 | |
| SCHEMBL2211497 | 0.89 | CPB2 (0.42) | CPB2GSRRNPEPHDAC1HDAC2 | |
| SCHEMBL1039473 | 0.89 | CPB2 (0.42) | CPB2GSRRNPEPHDAC1HDAC2 | |
| SCHEMBL17369161 | 0.89 | CPB2 (0.39) | CPB2GSRRNPEPHDAC1HDAC2 | |
| SCHEMBL7416589 | 0.89 | CPB2 (0.42) | CPB2GSRRNPEPHDAC1HDAC2 | |
| SCHEMBL6987450 | 0.88 | CPB2 (0.35) | CPB2GSRRNPEPHDAC1HDAC2 | |
| Ethylenediamine SCHEMBL17669758 | 0.88 | CPB2 (0.41) | CPB2GSRRNPEPHDAC1HDAC2 | |
| Ethylenediamine SCHEMBL17669759 | 0.88 | CPB2 (0.41) | CPB2GSRRNPEPHDAC1HDAC2 | |
| SCHEMBL6983943 | 0.88 | CPB2 (0.35) | CPB2GSRRNPEPHDAC1HDAC2 | |
| SCHEMBL1022347 | 0.84 | CPB2 (0.40) | CPB2GSRRNPEPHDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1133465-B1 | AMPHIPHILIC POLYAMINE COMPOUNDS | GENE THERAPY SYSTEMS INC (US) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003095641-A1 | INTRACELLULAR PROTEIN DELIVERY COMPOSITIONS AND METHODS OF USE | GENE THERAPY SYSTEMS, INC. (US) | 2003-11-20 | — | — | WO | disclosed |
| US-20030054007-A1 | Intracellular protein delivery compositions and methods of use | GENE THERAPY SYSTEMS, INC. | 2003-03-20 | — | — | US | disclosed |
| US-20030008813-A1 | Intracellular protein delivery compositions and methods of use | GENE THERAPY SYSTEMS, INC. | 2003-01-09 | — | — | US | disclosed |
| EP-1237581-A1 | USE OF CATIONIC LIPIDS FOR INTRACELLULAR PROTEIN DELIVERY | Gene Therapy Systems, Inc. (US) | 2002-09-11 | — | — | EP | disclosed |
| US-6433017-B1 | PROMOTERS FOR TRANSFECTION OF POLYNUCLEOTIDES AND POLYPEPTIDES INTO CELLS | GENE THERAPY SYSTEMS, INC. | 2002-08-13 | — | — | US | disclosed |
| US-6348499-B1 | POLYLACTAM POLYMERS FOR PROMOTING TRANSFECTION OF POLYNUCLEOTIDES AND POLYPEPTIDES INTO CELLS, AND FORMULATIONS COMPRISING SAID COMPOUNDS. | GENE THERAPY SYSTEMS, INC. | 2002-02-19 | — | — | US | disclosed |
| EP-1133465-A1 | AMPHIPHILIC POLYAMINE COMPOUNDS | Gene Therapy Systems, Inc. (US) | 2001-09-19 | — | — | EP | disclosed |
| WO-2001043778-A1 | USE OF CATIONIC LIPIDS FOR INTRACELLULAR PROTEIN DELIVERY | GENE THERAPY SYSTEMS, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
| WO-2000031022-A1 | AMPHIPHILIC POLYAMINE COMPOUNDS | GENE THERAPY SYSTEMS, INC. (US) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008813-A1 | Intracellular protein delivery compositions and methods of use | CHLSN, LCP2, CHMP4B | CPB2 2214/4885GSR 3090/4885RNPEP 631/4885 |
| US-20030054007-A1 | Intracellular protein delivery compositions and methods of use | CHLSN, LCP2, CHMP4B | CPB2 2214/4885GSR 3090/4885RNPEP 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.